Key information made simple
This summary needs review. Please check the official study record and contact the research team for details.
CompletedNCT03397134
2 Fixed Doses of MIN-101 for schizophrenia
This study is completed in the United States, in Bulgaria, in Poland, .... It is testing 2 Fixed Doses of MIN-101 for schizophrenia.
SchizophreniaDrugFrom 18 Years to 55 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
Check the study details
Check the official source, then confirm these points with the research team.
View official study record (opens in a new tab)
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: December 15, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 515
- Sponsor
- Minerva Neurosciences
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Poland, ...
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT03397134
- Official title
- A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Monotherapy, 12-Week Study to Evaluate the Efficacy and Safety of 2 Fixed Doses of MIN-101 in Adult Patients With Negative Symptoms of Schizophrenia, Followed by a 40-Week Open-Label Extension
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT03397134. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
View official study record (opens in a new tab)The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Bulgaria · 7 sites
- "State Psychiatric Hospital - Tserova Koria"; Department for Active Treatment of Severe Psychosis - male; Department for Active Treatment of Severe Psychosis - maleTserova Koria, Veliko Tarnovo DistrictSite status: Not listed — confirm with the team
- "Mental Health Center Prof. Dr. Ivan Temkov - Burgas" EOOD Department For Treatment of Emergency Psychiatry ConditionsBurgasSite status: Not listed — confirm with the team
- State Psychiatry Hospital - LovechLovechSite status: Not listed — confirm with the team
- State Psychiatry Hospital "Sveti Ivan Rilski" Department of General Psychiatry for adults "closed type" - males; Department of General Psychiatry for adults "closed type" - femalesNovi IskarSite status: Not listed — confirm with the team
- 'Mental Health Center Plovdiv"-EOOD Department for treatment of acute female/male psychoses with endogenous, exogenous, organic psychotic disturbances of the personalityPlovdivSite status: Not listed — confirm with the team
- Multiprofile Hospital for Active Treatment - Targovishte" AD Department of PsychiatryTargovishteSite status: Not listed — confirm with the team
- "Mental Health Center - Vratsa" General Psychiatric DepartmentVratsaSite status: Not listed — confirm with the team
Poland · 3 sites
- Samodzielny Publiczny Psychiatryczny zakład opieki zdrowotnej im Dr. Stanisława Deresza w ChoroszczyChoroszczSite status: Not listed — confirm with the team
- Medical University of Gdańsk, Department of Psychiatry UCKGdanskSite status: Not listed — confirm with the team
- Klinika Psychiatryczna InventivaTuszynSite status: Not listed — confirm with the team
Ukraine · 16 sites
- Communal Institution "Dnipropetrovsk Regional Clinical Hospital n.a. I.I. Mechnikov," Regional Centre for Psychosomatic Disorders based on Psychoneurological DepartmentDniproSite status: Not listed — confirm with the team
- Ivano-Frankivsk National Medical University (IFNMU) - Regional Psycho-Neurological Hospital #3Ivano-FrankivskSite status: Not listed — confirm with the team
- Kharkiv Railway Clinical Hospital N°1 of Branche "Health Center" of the Public joint stock company "Ukrainian Railway," Psychiatry DepartmentKharkivSite status: Not listed — confirm with the team
- State Institution "Institute of Neurology, Psychiatry and Narcology of National Academy of Medical Science of Ukraine," Department of Emergency Psychiatry and NarcologyKharkivSite status: Not listed — confirm with the team
- State Institution "Institute of Neurology, Psychiatry and Narcology of National Academy of Medical Science of Ukraine," Department of Neuroses and Borderline ConditionsKharkivSite status: Not listed — confirm with the team
- State Institution "Institute of Neurology, Psychiatry and Narcology of National Academy of Medical Sciences of Ukraine," Department of Clinical, Social and Child PsychiatryKharkivSite status: Not listed — confirm with the team
- Kyiv Regional Medical Incorporation "Psychiatry," Centre of Novel Treatment and Rehabilitation of Psychotic Disorders based on Department #29 and Department #30KyivSite status: Not listed — confirm with the team
- Communal Institution of Lviv Regional Council "Lviv Regional Clinical Psychiatric Hospital," Department #20LvivSite status: Not listed — confirm with the team
- Communal Institution of Lviv Regional Council "Lviv Regional Clinical Psychiatry Hospital," General Psychiatric Mixed Department #25LvivSite status: Not listed — confirm with the team
- Odessa Regional Medical Centre of Mental Health, Dept. #6 (male), Dept. #12 (female)OdesaSite status: Not listed — confirm with the team
- Kyiv Regional Medical Incorporation "Psychiatry," Centre of Novel Treatment and Rehabilitation of Psychotic Disorders based on Department #29 and Department #30OleksandrivkaSite status: Not listed — confirm with the team
- "Ukrainian medical stomatological academy," Chair of psychiatry, narcology and medical psychology based on Poltava Regional Clinical Psychiatric Hospital named after O.F. Maltsev, female acute general psych. dept. 5-b, male acute general psych. dept 2-aPoltavaSite status: Not listed — confirm with the team
- Communal Institution "Cherkasy Regional Psychiatric Hospital"SmilaSite status: Not listed — confirm with the team
- Municipal Institution Kherson Regional Psychiatric Hospital of Regional CouncilStepanovkaSite status: Not listed — confirm with the team
- Ternopil Regional Municipal Clinical Psychoneurological HospitalTernopilSite status: Not listed — confirm with the team
- Municipal Institution "Vinnytsya Regional Psychoneurological Hospital n.a. Acad. O.I. Yushchenko," Male Department No 14, Female Department No 15VinnytsiaSite status: Not listed — confirm with the team
United States · 13 sites
- Woodland Research NorthwestRogers, ArkansasSite status: Not listed — confirm with the team
- ProScience Research GroupCulver City, CaliforniaSite status: Not listed — confirm with the team
- Collaborative Neuroscience Network, LLC.Garden Grove, CaliforniaSite status: Not listed — confirm with the team
- Synergy Clinical CenterNational City, CaliforniaSite status: Not listed — confirm with the team
- Collaborative Neuroscience Network, LLC.Torrance, CaliforniaSite status: Not listed — confirm with the team
- Behavioral Clinical Research, IncNorth Miami, FloridaSite status: Not listed — confirm with the team
- Research Centers of America, LLCOakland Park, FloridaSite status: Not listed — confirm with the team
- Atlanta Center for Medical ResearchAtlanta, GeorgiaSite status: Not listed — confirm with the team
- Uptown Research Institute LLCChicago, IllinoisSite status: Not listed — confirm with the team
- Hassman Research Institute, LLC.Berlin, New JerseySite status: Not listed — confirm with the team
- The Nathan Kline Institute for Psychiatric ResearchOrangeburg, New YorkSite status: Not listed — confirm with the team
- InSite Clinical Research LLCDeSoto, TexasSite status: Not listed — confirm with the team
- Pillar Clinical Research LLCRichardson, TexasSite status: Not listed — confirm with the team
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Placebo Oral Tablet, Roluperidone 32 mg, Roluperidone 64 mg. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 55 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Minerva Neurosciences, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT01157351
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
This study is completed. It focuses on schizophrenia and currently lists study information in the United States.
CompletedEUCTR 2016-000061-23
A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
CompletedEUCTR 2008-002247-16
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.